- Trial phase
- Phase 1/2a
- Time to market
- At least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.
- Why 2/10
- No hard, dated catalyst is scheduled in the next ~12 months. The Phase 1/2a trial just began dosing on October 27, 2026, and initial data readout is likely years away. This is a very early-stage program at a diversified company with approved products, so impactScore is low.
OPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.
Price Chart
Executive Summary
OPK-8801001 is an investigational long-acting human growth hormone receptor antagonist being developed by OPKO Health (NASDAQ: OPK) for acromegaly, a rare endocrine disorder. The drug aims to be a once-weekly injectable alternative to the current daily standard-of-care pegvisomant (Somavert). On October 27, 2026, OPKO announced the first participant had been dosed in a first-in-human Phase 1/2a trial. Preclinical data presented at ENDO 2026 showed robust IGF-1 suppression and roughly 20-fold greater in vitro potency versus pegvisomant. However, the program is very early-stage (Phase 1/2a, just initiated) and represents a small part of OPKO Health's diversified business, which includes the approved product NGENLA (partnered with Pfizer), pharmaceutical sales in international markets, and a diagnostics business being sold to Labcorp. No near-term binary catalyst exists for this drug.
How It Works
OPK-8801001 is a growth hormone receptor antagonist. It blocks the receptor that growth hormone normally binds to, reducing the effects of excess growth hormone in the body. It is designed as a long-acting, once-weekly injection, in contrast to the current standard-of-care drug pegvisomant (Somavert), which requires daily injections.
Trial Status
First participant dosed on October 27, 2026, in a first-in-human Phase 1/2a study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamic activity (IGF-1 suppression). The trial is actively recruiting/enrolling. Preclinical data were presented at ENDO 2026 in June 2026.
The Two-Sided Case
Upcoming Catalysts
- Initial Phase 1/2a safety and pharmacodynamic data readout (no date announced; likely 12+ months away)
- Potential Phase 2/3 trial initiation (years away)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
OPKO HEALTH, INC. 8-K OPK ·Originating report